<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31684770</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3-4</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>245</EndPage><MedlinePgn>235-245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2019.1682613</ELocationID><Abstract><AbstractText><i>Background</i>: Few well-established factors are associated with risk of amyotrophic lateral sclerosis (ALS). We comprehensively evaluate prescription drugs use in administrative health claims from U.S. Medicare beneficiaries in relation to ALS risk to generate hypotheses for further research. <i>Methods</i>: This is a population-based case-control study of 10,450&#x2009;U.S. Medicare participants (ages 66-89 years) diagnosed with ALS, based on Medicare Parts A and B fee-for-service claims, between 1 January 2008, and 31 December 2014, and 104,500 controls (1:10 ratio) frequency-matched on age, sex, and selection year. Odds ratios (ORs) for the ALS association with 685 prescription drugs were estimated using logistic regression models for both a one- and three-year lag period. Covariates included demographic characteristics and key comorbidities, among other factors. Prescription drug use was based on Medicare Part D claims. We adjusted for multiple comparisons using a Bonferroni correction. Additional <i>a priori</i> analyses of sex hormone drugs were also undertaken. <i>Results</i>: In the large drug screen, we found 10 drugs significantly associated with lower ALS risk after the multiple-testing correction in a one-year and three-year lag analysis. These included several drugs for hypertension, diabetes, and cardiovascular disease. In a separate <i>a priori</i> inquiry of sex hormone drugs, tamoxifen was related to lower ALS risk, and testosterone to a higher risk in women. <i>Conclusions</i>: These associations warrant replication in databases that include information on the severity and duration of medical conditions underlying drug use, and drug use over a longer portion of individuals' lifespans, to further help evaluate confounding by indication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Ruth M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, NIH, DHHS, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuncl</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biology, University of the Redlands, Redlands, CA, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Check</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, NIH, DHHS, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahoon</LastName><ForeName>Elizabeth K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, NIH, DHHS, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Donna R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Control and Population Sciences, NIH, DHHS, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>D Michal</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>National Cancer Institute, Division of Cancer Epidemiology and Genetics, NIH, DHHS, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 CA999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054524" MajorTopicYN="N">Medicare Part D</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="N">Prescription Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Medicare</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">medications</Keyword><Keyword MajorTopicYN="N">population based</Keyword><Keyword MajorTopicYN="N">risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31684770</ArticleId><ArticleId IdType="mid">NIHMS1619770</ArticleId><ArticleId IdType="pmc">PMC9930913</ArticleId><ArticleId IdType="doi">10.1080/21678421.2019.1682613</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12: 310&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis &#x2014; United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018; 93: 1617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Palomo Ruiz MD, Perez DI, Gil C. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2017;26: 403&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">28277881</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lat Scler Fr. 2018; 19:538&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31112080</ArticleId></ArticleIdList></Reference><Reference><Citation>Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174: 860&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203375</ArticleId><ArticleId IdType="pubmed">21821540</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:877&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646848</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonito AJ, Bann C, Eicheldinger C, Carpenter L. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. Rockville, MD: Agency for Healthcare Research and Quality and Center for Medicare and Medicaid Services; 2008.</Citation></Reference><Reference><Citation>Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997&#x2013;2011. Neurol Clin Pract. 2013;3:313&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3787117</ArticleId><ArticleId IdType="pubmed">24195020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Guennoc AM, Veyrat-Durebex C, Gordon PH, Andres CR, Camu W, et al. Amyotrophic lateral sclerosis: a hormonal condition?. Amyotroph Lateral Scler. 2012; 13:585&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22873563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kioumourtzoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol. 2015;72:905&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4975611</ArticleId><ArticleId IdType="pubmed">26030836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22:1436&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Lee JKW, Lee C. Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. J Neurol. 2019; 266:2233.</Citation><ArticleIdList><ArticleId IdType="pubmed">31152300</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F, d&#x2019;Errico A, Carna P, Calvo A, Costa G, Chio A. The role of pre-morbid diabetes on developing amyotrophic lateral sclerosis. Eur J Neurol. 2018; 25: 164&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a mendelian randomization study [Internet]. Hum Mol Genet. 2019; 28:688&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85:470&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Osman EY, Washington CW, Simon ME, Megiddo D, Greif H, Lorson CL. Analysis of azithromycin monohydrate as a single or a combinatorial therapy in a mouse model of severe spinal muscular atrophy. J Neuromuscul Dis. 2017;4:237&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">28598854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur P, Muthuraman A, Kaur M. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives. ACS Chem Neurosci. 2015;6:508&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25680080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi Lee C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk. JAMA Neurol. 2015;72: 40&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383557</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Yadav A, Chaturvedi RK. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun. 2017;483:116&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">27514452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosley RL, Gendelman HE. Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders. Exp Neurol. 2010;222:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824918</ArticleId><ArticleId IdType="pubmed">20044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufir&#xed; M, Gil-Bea FJ, Fernandez-Torr&#xf3;n R, Poza JJ, Mu&#xf1;oz-Blanco JL, Rojas-Garc&#xed;a R, et al. ALS: A bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol. 2016;142:104&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">27236050</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha C, Duncan K, Walters B. Neuroprotective actions of brain aromatase. Front Neuroendocrinol. 2009;30:106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700852</ArticleId><ArticleId IdType="pubmed">19450619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney JPK, Visser AE, D&#x2019;Ovidio F, Vermeulen R, Beghi E, Chio A, et al. A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology. 2017;89:1283&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28835399</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, Liu Y, Sun C, Zheng Q, Hao P, Zhai J, et al. Effects of ovariectomy in an hSOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS). Med Sci Monit. 2018;24:678&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806477</ArticleId><ArticleId IdType="pubmed">29394243</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsini M, Oliveira AB, Nascimento OJM, Reis CHM, Leite MAA, De Souza JA, et al. Amyotrophic lateral sclerosis: new perpectives and update. Neurol Int. 2015;7: 5885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4591493</ArticleId><ArticleId IdType="pubmed">26487927</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Dong H, Liu Y, Yan L, Sun C, Hao P, et al. Raloxifene, a promising estrogen replacement, limits TDP-25 cell death by enhancing autophagy and suppressing apoptosis. Brain Res Bull. 2018; 140:281&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29807145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargiulo-Monachelli GM, Sivori M, Meyer M, Sica R, De Nicola A, Gonzalez-Deniselle MC. Circulating gonadal and adrenal steroids in amyotrophic lateral sclerosis: possible markers of susceptibility and outcome. Horm Metab Res. 2014;46:433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24806746</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria - a population-based study. Arch Neurol. 2000;57:1171&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10927797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos RM, Piehl F, Kamel F, Fang FC. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>